Suppr超能文献

相似文献

2
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
3
Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. doi: 10.18553/jmcp.2014.20.4.346.
4
The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Crit Rev Oncol Hematol. 2016 Mar;99:91-9. doi: 10.1016/j.critrevonc.2015.12.002. Epub 2015 Dec 10.
5
No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.
Mol Oncol. 2014 Sep 12;8(6):1140-58. doi: 10.1016/j.molonc.2014.07.027. Epub 2014 Aug 15.
6
[Targeted therapies for melanoma].
Hautarzt. 2014 Jul;65(7):600-6. doi: 10.1007/s00105-013-2735-6.
7
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Crit Rev Oncog. 2016;21(1-2):83-91. doi: 10.1615/CritRevOncog.2016017150.
8
Nivolumab: A Review in Advanced Melanoma.
Drugs. 2015 Aug;75(12):1413-24. doi: 10.1007/s40265-015-0442-6.

引用本文的文献

1
Evodiamine inhibits growth of vemurafenib drug-resistant melanoma via suppressing IRS4/PI3K/AKT signaling pathway.
J Nat Med. 2024 Mar;78(2):342-354. doi: 10.1007/s11418-023-01769-9. Epub 2024 Feb 7.
2
MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas.
Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2208900119. doi: 10.1073/pnas.2208900119. Epub 2022 Dec 1.
3
Converting melanoma-associated fibroblasts into a tumor-suppressive phenotype by increasing intracellular Notch1 pathway activity.
PLoS One. 2021 Mar 11;16(3):e0248260. doi: 10.1371/journal.pone.0248260. eCollection 2021.
4
Three-dimensional multicellular cell culture for anti-melanoma drug screening: focus on tumor microenvironment.
Cytotechnology. 2021 Feb;73(1):35-48. doi: 10.1007/s10616-020-00440-5. Epub 2020 Nov 20.
5
HI-511 overcomes melanoma drug resistance targeting AURKB and BRAF V600E.
Theranostics. 2020 Aug 1;10(21):9721-9740. doi: 10.7150/thno.44342. eCollection 2020.
6
A blood test to identify when melanoma metastasizes: a reality for melanoma management?
Melanoma Manag. 2014 Aug;1(1):11-14. doi: 10.2217/mmt.14.11. Epub 2014 Sep 5.
7
Anorectal mucosal melanoma.
Oncotarget. 2018 Jan 2;9(9):8785-8800. doi: 10.18632/oncotarget.23835. eCollection 2018 Feb 2.
8
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.
9
BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma.
Oncotarget. 2017 May 9;8(41):69477-69492. doi: 10.18632/oncotarget.17704. eCollection 2017 Sep 19.
10
Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
Oncogene. 2018 Jan 25;37(4):439-449. doi: 10.1038/onc.2017.346. Epub 2017 Oct 2.

本文引用的文献

1
The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
Clin Cancer Res. 2013 Oct 1;19(19):5320-8. doi: 10.1158/1078-0432.CCR-13-0259.
2
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
Clin Cancer Res. 2013 Oct 1;19(19):5310-9. doi: 10.1158/1078-0432.CCR-13-0142.
3
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143.
4
Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy.
Clin Cancer Res. 2013 Oct 1;19(19):5292-9. doi: 10.1158/1078-0432.CCR-13-0261.
5
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).
Clin Cancer Res. 2013 Sep 1;19(17):4868-78. doi: 10.1158/1078-0432.CCR-13-0827. Epub 2013 Jul 5.
6
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
7
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.
8
Hepatotoxicity with combination of vemurafenib and ipilimumab.
N Engl J Med. 2013 Apr 4;368(14):1365-6. doi: 10.1056/NEJMc1302338.
10
Agonistic CD40 antibodies and cancer therapy.
Clin Cancer Res. 2013 Mar 1;19(5):1035-43. doi: 10.1158/1078-0432.CCR-12-2064.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验